Auxilius is a technology company.
Auxilius has raised $10.0M across 1 funding round.
Auxilius has raised $10.0M in total across 1 funding round.
Auxilius has raised $10.0M in total across 1 funding round.
Auxilius's investors include AlleyCorp, Alt Capital, Bullpen Capital, C2 Investment, Electric Capital, Founders Fund, G20 Ventures, Khosla Ventures, MKT1 Capital, Plaid, Renegade Partners, Ribbit Capital.
Auxilius is a Series A SaaS company founded in 2020 that provides R&D financial management software for the biopharma industry, specializing in automating budgeting, planning, forecasting, accruals, and clinical trial financial management (CTFM).[1][2][3][4] Its platform integrates clinical data, invoices, and vendor estimates to replace error-prone spreadsheets, enabling finance, accounting, and clinical operations teams to manage biopharma's largest and most variable costs—clinical trials and CMC—with improved accuracy, audit readiness, and efficiency.[1][2][5] Serving over 50 biotech and pharmaceutical companies, Auxilius achieved 800% year-over-year ARR growth in 2023 and raised $10 million in additional financing led by SignalFire, demonstrating strong growth momentum in a high-stakes sector.[1][3]
Auxilius was founded in 2020 in New York by CEO and co-founder Adam Weisman and his team, emerging from the need to address inefficiencies in biopharma R&D finance, where clinical trial budgets—often the industry's biggest expense—are managed via cumbersome spreadsheets prone to errors and crashes.[1][3][4] The idea crystallized around creating the first CTFM software to automate workflows for life science finance, accounting, and clinical operations, filling a critical gap in forecasting accuracy and expense management.[1] Early traction built through deep engagement in the life sciences community via conferences and events, leading to partnerships with over 50 biopharma firms and explosive 800% ARR growth in 2023, culminating in a $10 million funding round.[1][3]
Auxilius rides the wave of digital transformation in biopharma R&D, where clinical trials represent the largest, most unpredictable expense amid rising costs and regulatory scrutiny.[1][3] Timing aligns with post-pandemic biotech funding recovery and AI-driven efficiencies, as firms seek tools to extend runway, optimize spending, and accelerate innovation—Auxilius directly tackles spreadsheet chaos that hampers 50+ customers.[1][2] Market forces like SOX compliance demands, audit pressures, and CMC complexity favor its compliant automation, positioning it as a category creator in CTFM.[1][5] By empowering smarter resource allocation, Auxilius influences the ecosystem, enabling faster medical breakthroughs and operational efficiency in a $100B+ clinical trials market.[1]
Auxilius is poised to dominate CTFM as biopharma scales AI-integrated trials and faces tighter budgets, with plans to invest in product innovation and go-to-market expansion.[1][3] Trends like AI-enhanced forecasting and global trial complexity will amplify demand, potentially driving further ARR surges and acquisitions by larger ERP players. Its influence could evolve from niche innovator to industry standard, revolutionizing R&D finance and fueling biotech momentum—much like how it transformed spreadsheets into strategic assets for its growing customer base.[1][5]
Auxilius has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $10.0M Series A | AlleyCorp, Alt Capital, Bullpen Capital, C2 Investment, Electric Capital, Founders Fund, G20 Ventures, Khosla Ventures, MKT1 Capital, Plaid, Renegade Partners, Ribbit Capital, Scalar Capital, Susa Ventures, Vinyl Capital, Work-Bench, XYZ Venture Capital, Derrick Li, Matt Macinnis, Michael Ma, Parker Conrad |